Neurology focused Multi-modal LLM
NeuroDiscovery AI has developed a specialized multi-modal large language model (LLM) platform (NeuroLLM) exclusively designed for pharmaceutical applications. Our proprietary multi-modal LLM technology integrates EHR, Billing/Claims, Imaging (MRI, CT, PET EEG, EMG, and others) information into a unified AI system optimized for the pharmaceutical drug lifecycle from discovery to post-marketing activities.
Unlike general-purpose AI companies, NeuroDiscovery AI is purpose-built for deep pharmaceutical industry integration, focusing on creating specialized multi-modal LLM capabilities that directly address the unique data types and complex problems in the drug lifecycle. By combining cutting-edge multi-modal LLM architecture with pharmaceutical domain expertise, we provide Lifesciences companies with a competitive advantage that general AI platforms cannot match.
Key Features
Data
The model is currently being trained on a comprehensive dataset of 5 million U.S. Neurology patients data, encompassing Clinical, Billing/Claims, Laboratory Results, Radiology Reports, Genetic Results, EEG, EMG, and Radiology Images (exceeding 400 million images).
NDAI-neuro-med
NeuroDiscovery AI has developed the world’s most precise neuroscience embedding model for domain-specific retrieval.
Domain Adaptation and Fine Tuning
The foundational multi-modal LLM has been adapted to the Neurology domain and fine-tuned for specific Neurology conditions.
.svg){kind=small}
Knowledge Graphs
NeuroLLM domain knowledge is further enhanced by the utilization of knowledge graphs constructed on NeuroDiscovery’s 5 million patient data.
Stay Informed
Subscribe to our research newsletter for updates on new datasets, research findings, and collaboration opportunities